Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDR in Previously Untreated Waldenstroms Macroglobulinemia
NCT00832234Phase 2
Key facts
- Status
- Completed
- Start
- Sep 2006
- Primary completion
- Jun 2010
- Countries
- 1
- Modality
- Small Molecules, Modified Peptides
- Drugs
- bortezomib
- Conditions
- Waldenström macroglobulinemia (WM)
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in Waldenström macroglobulinemia (WM). Primary endpoint: Overall Response Rate at 2 years. Started Sep 2006; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
BDR Combination Therapy
Bortezomib, Dexamethasone, and Rituximab combination.
03
Who it enrols
Previously untreated patients with a clinicopathological diagnosis of Waldenstroms macroglobulinemia who meet specific indications for treatment (e.g., symptomatic disease, cytopenias, or high M-protein) and have CD20 positive disease.
04
Endpoints
Primary
Overall Response Rate
Secondary
Time to Progression
Safety and Tolerability
Beyond the preview
Go deeper on NCT00832234.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00832234.